PHS Issues Treatment Guidelines for Tobacco Dependency

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 9
Volume 9
Issue 9

WASHINGTON-The US Public Health Service (PHS) has released “Treating Tobacco Use and Dependence: A Clinical Practice Guideline,” which offers trial-based data on first- and second-line therapies to help smokers quit.

WASHINGTON—The US Public Health Service (PHS) has released “Treating Tobacco Use and Dependence: A Clinical Practice Guideline,” which offers trial-based data on first- and second-line therapies to help smokers quit.

A nongovernment panel of experts compiled the publication. The guideline stresses that treatments are both clinically effective and cost-effective, and urges health insurers to cover tobacco-dependency therapies identified in the guideline. For copies, call 1-800-358-9295 or go to http://www.surgeongeneral.gov/tobacco/default.htm.

Articles in this issue
Epirubicin Associated With Prolonged Survival in the Neoadjuvant Setting for Breast Cancer
Soy’s Effect on Breast Cancer Remains Uncertain
Epirubicin-containing Regimens Reported to Prolong Survival in Breast Cancer Patients
Comprehensive Eye Cancer Website Meets Needs of Both Patients and Physicians
STAR Enrollment Tops 6,000 in First Year of Recruitment
New rhTPO Being Tested in Three Trials
New Research Centers Target How Market Forces Affect Health Care
Irinotecan/Gemcitabine Combination Advances to Phase III Trials in Advanced Pancreatic Cancer
Aromatase Inhibitors Actively Studied in Hormone-Dependent Breast Cancer
PRIMATOM System Combines CT Scanning With Radiation Therapy
Tobacco Boosts In-Store Advertising
Irinotecan and Radiotherapy Active in Non–Small-Cell Lung Cancer
Irinotecan/Cisplatin Produces Better Survival Than Etoposide/Cisplatin in Extensive SCLC
Higher CR Rates in CLL When Rituximab Added to FC Therapy
Device Allows Comparison of Prognostic Gene Clusters
Recent Videos
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content
We’re helping to train healthcare professionals from some of these countries, at least on the clinical side, and giving them an idea of how manufacturing happens.

How Are Cellular Therapeutics Distributed in Global Oncology Settings?

Tim Cortese
October 16th 2025
Article

In lower- and middle-income countries, accessibility, cost, and talent are obstacles to broadly implementing cellular therapeutics into cancer care.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

The safety profile of pembrolizumab plus chemotherapy with or without bevacizumab was consistent with that observed in previous studies.

Pembrolizumab/Chemotherapy Improves Survival in Recurrent PROC

Roman Fabbricatore
October 16th 2025
Article

The safety profile of pembrolizumab plus chemotherapy with or without bevacizumab was consistent with that observed in previous studies.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

EO2463 combines 4 synthetic peptides that correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with CD20, CD22, CD37, and CD268, the B lymphocyte-specific lineage markers.

FDA Grants FTD to Novel Cancer Vaccine in Low Tumor Burden Follicular Lymphoma

Tim Cortese
October 16th 2025
Article

The EO2463 off-the-shelf immunotherapy achieved an overall response rate of 46% in patients with follicular lymphoma considered to be in the “watch-and-wait” setting.

The most common any-grade TRAEs were fatigue (56%), diarrhea (33%), maculopapular rash (30%), pruritus (22%), anemia (19%), arthralgia (19%), and decreased lymphocyte count (19%).

Single-Agent PD-1 Blockade Therapy Improves Responses in Desmoplastic Melanoma

Tim Cortese
October 15th 2025
Article

Single-agent pembrolizumab achieved an ORR of 89%, with a 37% CR rate, in patients with advanced desmoplastic melanoma in the phase 2 SWOG S1512 trial.